Gilead (GILD) Announced Interim Phase 2 Data on Hepatitis Drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Notable ETF Movers of the Day 11/12: (IBB) Higher; (XLU) (ITB) Lower
November 12, 2012 12:58 PM ESTGainers:
iShares Nasdaq Biotechnology (Nasdaq: IBB) gained 2 percent to 132.57. The move is tied to shares of Gilead Sciences (Nasdaq: GILD) which gained 12 percent on positive results for its drug combo 7977/5885 for treatment of hepatitis C. Shares of... More
Deutsche Bank Maintains Buy on Gilead Sciences (GILD) after Strong Hepatitis C Combo Data
November 12, 2012 8:39 AM ESTDeutsche Bank reiterated its Buy rating and $75 price target on Gilead Sciences (NASDAQ: GILD) following positive data from the '7977/'5885 combo in treatment-naïve genotype 1 Hepatitis C patients, showing 100 percent (n=25/25) remained HCV RNA undetectable four weeks after completing therapy (SVR4).
Commenting on... More
